Comorbidity burden conditions the prognostic performance of D-dimer in elderly patients with acute pulmonary embolism

Hernan Polo Friz1, Valentina Pezzetti2, Annalisa Orenti3

  • 1Internal Medicine, Medical Department, Vimercate Hospital, ASST di Vimercate, Vimercate, Italy; Research and Study Center of the Italian Society of Angiology and Vascular Pathology (Società Italiana di Angiologia e Patologia Vascolare, SIAPAV), Milan, Italy.

Insights

Comorbidities impact D-dimer

Area of Science:

  • Cardiology
  • Geriatrics
  • Pulmonary Medicine

Background:

  • D-dimer's prognostic accuracy in acute Pulmonary Embolism (APE) may be affected by comorbidities.
  • Comorbidity burden (CB) can influence the predictive value of D-dimer for mortality in elderly APE patients.

Purpose of the Study:

  • To investigate how comorbidity burden, assessed by the Charlson Comorbidity Index (CCI), affects D-dimer's prognostic ability.
  • To evaluate D-dimer's effectiveness in predicting 30 and 90-day mortality in hemodynamically stable, elderly APE patients with varying comorbidity levels.

Main Methods:

  • Retrospective cohort study of 162 elderly patients (>65 years) with normotensive APE.
  • Comorbidity burden categorized as Low CB (CCI ≤1) and High CB (CCI >1).
  • Analysis of D-dimer's prognostic performance using Area Under the Curve (AUC) and Net Reclassification Improvement (NRI), with and without the simplified Pulmonary Embolism Severity Index (sPESI).

Main Results:

  • Higher D-dimer levels correlated with increased 30 and 90-day mortality risk in the overall cohort.
  • D-dimer significantly improved 30-day mortality prediction in patients with Low CB when added to sPESI (AUC increase, significant NRI).
  • D-dimer did not significantly improve mortality prediction in patients with High CB, for both 30 and 90-day outcomes.

Conclusions:

  • Comorbidities significantly influence the prognostic performance of D-dimer in elderly patients with normotensive APE.
  • D-dimer is a more effective predictor of mortality in elderly APE patients with low comorbidity burden.
  • Multimarker strategies incorporating D-dimer and comorbidity assessment are recommended for improved risk stratification in this population.
Abstract

Related Concept Videos

Pulmonary Embolism I: Introduction01:29

Pulmonary Embolism I: Introduction

Pulmonary embolism (PE) occurs when a thrombus, fat or air embolus, amniotic fluid, or tumor tissue blocks one or more pulmonary arteries. These blockages originate in the venous system or the right side of the heart.EtiologyPE primarily arises from deep vein thrombosis (DVT) and other hypercoagulable states, such as inherited thrombophilias. Additional etiological factors include venous stasis, commonly seen in obesity, and endothelial injury from surgery and trauma. Less common causes include...
746
Pulmonary Embolism III: Nursing Management01:27

Pulmonary Embolism III: Nursing Management

A pulmonary embolism occurs when a thrombus, amniotic fluid, tumor tissue, fat, or air embolus blocks one or more pulmonary arteries. Effective nursing management and patient education are crucial for improving outcomes and preventing recurrence.Nursing management starts with obtaining a comprehensive patient history, particularly noting any history of deep vein thrombosis (DVT). Assess for clinical manifestations, including dyspnea, chest pain, crackles, heart murmurs, and signs of right-sided...
451
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
469
Pulmonary Tuberculosis I01:29

Pulmonary Tuberculosis I

Tuberculosis, often called TB, is a contagious illness primarily caused by Mycobacterium tuberculosis. It mainly affects the lung parenchyma but can also impact other body parts.
Causative Organism
The primary infectious agent causing tuberculosis is Mycobacterium tuberculosis, a slow-growing, acid-fast, aerobic rod that exhibits sensitivity to heat and ultraviolet light. Instances of Mycobacterium bovis and Mycobacterium avium contributing to the development of TB infection are rare.
Mode of...
991
Pulmonary Tuberculosis II01:28

Pulmonary Tuberculosis II

Tuberculosis, or TB, is a bacterial infectious disease caused by Mycobacterium tuberculosis. While its primary impact is on the lungs, leading to pulmonary tuberculosis, it can also affect various other organs, a condition referred to as extrapulmonary tuberculosis.
Here is a detailed explanation of its pathophysiology:
Transmission: The process begins when a person inhales droplet nuclei containing M. tuberculosis. These are typically released into the air when an individual with pulmonary or...
1.5K
Pulmonary Tuberculosis V01:28

Pulmonary Tuberculosis V

Medical management of tuberculosis (TB) patients involves a comprehensive approach that includes diagnosis, treatment, and monitoring. The specific strategies can vary depending on the type of tuberculosis (latent or active), the patient's overall health status, and other considerations.
Latent tuberculosis infection occurs when TB bacteria are present in a person's body, but are not causing illness or symptoms. It is not contagious, and preventive treatment is crucial to avoid the...
630